Royce & Associates LP Has $9.08 Million Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Royce & Associates LP increased its Centessa Pharmaceuticals stake by 46.7% in the fourth quarter, buying 115,486 additional shares to hold 362,873 shares worth about $9.08 million.
• Other hedge funds also boosted or initiated positions, and institutional investors now own 82.01% of Centessa’s stock, signaling strong institutional interest in the biotech company.
• Centessa’s stock recently traded near its 52-week high at $39.81, but the company reported a quarterly loss of ($0.52) per share, missing analyst expectations; the stock currently carries a Hold consensus rating with a $41.33 price target.

Royce & Associates LP raised its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 46.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 362,873 shares of the company's stock after buying an additional 115,486 shares during the period. Royce & Associates LP owned about 0.27% of Centessa Pharmaceuticals worth $9,075,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of CNTA. PSP Research LLC acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $547,000. GSA Capital Partners LLP increased its holdings in shares of Centessa Pharmaceuticals by 76.5% in the fourth quarter. GSA Capital Partners LLP now owns 33,104 shares of the company's stock valued at $828,000 after purchasing an additional 14,343 shares in the last quarter. DNB Asset Management AS increased its holdings in shares of Centessa Pharmaceuticals by 41.8% in the fourth quarter. DNB Asset Management AS now owns 12,746 shares of the company's stock valued at $319,000 after purchasing an additional 3,758 shares in the last quarter. Sigma Planning Corp acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $225,000. Finally, B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $961,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $39.81 on Friday. The firm has a market cap of $5.94 billion, a PE ratio of -22.24 and a beta of 1.13. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $10.95 and a 1-year high of $40.26. The company has a fifty day moving average price of $37.52 and a 200 day moving average price of $29.87.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.14). Research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Gregory M. Weinhoff sold 73,196 shares of the company's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the completion of the transaction, the insider directly owned 65,925 shares of the company's stock, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Karen M. Anderson sold 120,029 shares of the company's stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares of the company's stock, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 309,112 shares of company stock valued at $8,424,535. Company insiders own 4.09% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on CNTA shares. Needham & Company LLC lowered shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, March 31st. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an "overweight" rating to an "equal weight" rating and raised their price target for the company from $35.00 to $42.00 in a report on Monday, April 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Stephens lowered shares of Centessa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 31st. Finally, Truist Financial lowered shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating and set a $38.00 price target for the company. in a report on Monday, April 13th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $41.33.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.